Signal Transduction Pathways for Mouse Platelet Membrane Adhesion Receptors

Introduction

The study of genetic bleeding disorders provided the first link between platelet functions and specific membrane glycoproteins. Two examples are well known and have been the subject of numerous reviews. First, Glanzmann’s thrombasthenia is a bleeding disorder caused by a defect of platelet aggregation in which the glycoprotein αIIbβ3 (GP IIb-IIIa) is either lacking or is expressed but is defective.¹ We now know that αIIbβ3 exists on the surface of unstimulated platelets in an inactive form but, through a process known as “inside-out” signaling, responds to platelet stimulation to become a receptor for soluble fibrinogen and von Willebrand factor (vWF) to mediate platelet aggregation. αIIbβ3 is also known to bind immobilized fibrinogen and, through a process known as “outside-in” signaling, to induce platelet stimulation.² A second example is Bernard-Soulier syndrome, a bleeding disorder caused by the failure of platelets to bind to subendothelial matrices due to the lack of or defective GP Ib-IX-V.³ It is now known that GP Ib-IX-V binds to vWF to mediate the adhesion of unstimulated platelets to injured blood vessel walls.^4,5 GP Ib-IX-V interactions also induce platelet stimulation, a process mediated by signaling through GP Ib-IX-V.⁶ The mechanisms responsible for the binding of adhesive proteins to αIIbβ3 and GP Ib-IX-V are beginning to be understood and, as such, targets for therapeutic intervention have been identified. Three parenteral αIIbβ3 antagonists have demonstrated a therapeutic benefit in large-scale clinical trials of acute coronary syndromes, including unstable angina, non Q-wave myocardial infarction, and percutaneous intervention, and are now commercially available.⁷ Many orally available αIIbβ3 antagonists are presently in clinical trials. Although GP Ib antagonists have not been pursued as aggressively, animal studies have shown that they do have a proven antithrombotic benefit.⁸ Despite these advances in the understanding of glycoprotein ligand binding and development of therapeutic antagonists of adhesive protein receptors, the mechanisms responsible for transducing signals through these receptors have remained elusive.

It is now established that signal transduction reactions through αIIbβ3 and GP Ib-IX-V are not only involved in platelet aggregation to cause vessel occlusions, but also that glycoprotein signaling affects thrombus growth and stability, as well as the biology and perhaps the pathology of the vessels in which aggregates occur. In one example, platelet-derived growth factor (PDGF), secreted in response to αIIbβ3 signaling from the α-granules of aggregated platelets, is a primary smooth muscle cell mitogen and is believed to be involved not only in the response to vascular injury but also in atherosclerotic lesion progression.^9,10 In another example, CD 154 (previously termed CD40 ligand) redistributes from α-granule membranes to the surface of aggregated platelets in response to αIIbβ3 signaling.¹¹ CD 154 is an important inflammatory mediator that induces the release of cytokines from endothelial and smooth muscle cells, initiates vascular inflammation, and participates in atherosclerotic lesion progression.¹² A third example involves the assembly of prothrombinase and factor Xase on the surface of aggregated platelets, enabling platelet thrombi to be procoagulant and accounting for the apparent anticoagulant activity of αIIbβ3 antagonists.^13,14 In addition, platelet aggregates also display fibrinogen and vWF bound to platelet membrane glycoproteins that function to recruit additional platelets and, therefore, enhance thrombus growth.¹⁵ More recent data also indicate that platelet aggregation induces de novo protein synthesis.^16,17 These and other events are secondary to the initial adhesion and aggregation reactions of platelets and are consequences of signaling reactions induced by the adhesion and aggregation receptors. Thus, characterization of the membrane glycoprotein signal transduction pathways has become essential, not only to understand platelet function, but also to determine whether there are additional ways by which platelet-mediated pathologies can be regulated.

Platelet membrane glycoprotein signaling reactions either do not occur in nucleated cells normally used for transfection studies or are insufficiently characterized. Accordingly, the use of genetics to study mechanisms of platelet adhesive protein receptor signaling has been limited. The advent of technologies that facilitate genetic manipulations in the mouse genome has produced new ways to define protein function and determine the structure-function relationships of individual proteins and is proving of value in unraveling signal transduction pathways in platelets. Although one should always be cautious in extrapolating data from mouse to human platelets (as demonstrated by the PAR receptors, see below), it is impressive that much of what has been learned about platelets appears to apply to both mouse and human. Indeed, this review summarizes the status of genetic manipulations of the mouse genome that have contributed to our understanding of platelet membrane adhesion receptor signaling in platelets.

• References

• 1 French DL. The molecular genetics of Glanzmann’s thrombasthenia. Platelets. 1998; 9: 5-20.
• 2 Shattil S, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998; 91: 1-14.
• 3 Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998; 91: 4397-4418.
• 4 Savage B, Saldivar E, Ruggeri Z. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996; 84: 289-297.
• 5 Verkleij MW, Morton LF, Knight CG, de Groot PG, Barnes MJ, Sixma JJ. Simple collagen-like peptides support platelet adhesion under static but not under flow conditions: interaction via alpha2 beta1 and von Willebrand factor with specific sequences in native collagen is a requirement to resist shear forces. Blood 1998; 91: 3808-3816.
• 6 Casonato A, De Marco L, Mazzucato M, De Angelis V, De Roia D, Fabris F, Ruggeri ZM, Girolami A. A new congenital platelet abnormality characterized by spontaneous platelet aggregation, enhanced von Willebrand factor platelet interaction, and the presence of all von Willebrand factor multimers in plasma. Blood 1989; 74: 2028-2033.
• 7 Scarborough R, Kleiman N, Phillips D. Platelet glycoprotein IIb-IIIa antagonists - what are the relevant issues concerning thir pharmacology and clinical use?. Circulation.. In press.
• 8 Yamamoto H, Vreys I, Stassen JM, Yoshimoto R, Vermylen J, Hoylaerts MF. Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb Haemost. 1998; 79: 202-210.
• 9 Ross R, Masuda J, Raines E, Gown A, Katsuda S, Sasahara M, Malden L, Masuko H, Sato H. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science 1990; 248: 1009-1012.
• 10 Kraiss L, Raines E, Wilcox J, Seifert R, Barrett T, Kirkham T, Hart C, Bowen-Pope D, Ross R, Clowes A. Regional expression of the platelet-derived growth factor and its receptors in a primate graft model of vessel wall assembly. J Clin Invest. 1993; 92: 338-348.
• 11 Henn V, Slupsky J, Grafe M, Anagnostopoulos I, Forste RR, Muller-Berghaus G, Kroczek R. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
• 12 Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 1998; 394: 200-203.
• 13 Reverter J, Beguin S, Kessels R, Hemker H, Coller B. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest. 1996; 98: 863-874.
• 14 van’t Veer C, DiLorenzo M, Lock J, Mann K. Effect of platelet inhibitors on thrombin generation. Blood 1997; 90 (Suppl): 29a.
• 15 Gawaz MP, Loftus JC, Bajt ML, Frojmovic MM, Plow EF, Ginsberg MH. Ligand bridging mediates integrin alpha IIb beta 3 (platelet GPIIB- IIIA) dependent homotypic and heterotypic cell-cell interactions. J Clin Invest. 1991; 88: 1128-1134.
• 16 Weyrich AS, Dixon DA, Pabla R, Elstad MR, McIntyre TM, Prescott SM, Zimmerman GA. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci USA. 1998; 95: 5556-5561.
• 17 Pabla R, Weyrich AS, Dixon DA, Bray PF, McIntyre TM, Prescott SM, Zimmerman GA. Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets. J Cell Biol. 1999; 144: 175-184.
• 18 Fox JE, Shattil SJ, Kinlough-Rathbone RL, Richardson M, Packham MA, Sanan DA. The platelet cytoskeleton stabilizes the interaction between alphaIIbbeta3 and its ligand and induces selective movements of ligand-occupied integrin. J Biol Chem. 1996; 271: 7004-7011.
• 19 Clark EA, Shattil SJ, Ginsberg MH, Bolen J, Brugge JS. Regulation of the protein tyrosine kinase pp72syk by platelet agonists and the integrin alpha IIb beta 3. J Biol Chem. 1994; 269: 28859-28864.
• 20 Lipfert L, Haimovich B, Schaller MD, Cobb BS, Parsons JT, Brugge JS. Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets. J Cell Biol. 1992; 119: 905-912.
• 21 Phillips DR, Jennings LK, Edwards HH. Identification of membrane proteins mediating the interaction of human platelets. J Cell Biol. 1980; 86: 77-86.
• 22 Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: the responsive integrin. Cell. 1991; 65: 359-362.
• 23 Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkel Saito T, Tybulewicz VL, Watson SP. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. Embo J. 1997; 16: 2333-2341.
• 24 Watson SP, Gibbins J. Collagen receptor signaling in platelets: extending the role of the ITAM. Immunol Today. 1998; 19: 260-264.
• 25 Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest. 1989; 84: 1440-1445.
• 26 Clements JL, Lee JR, Gross BR, Yang B, Olson JD, Sandra A, Watson SP, Lentz SR, Koretzky GA. Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice. J Clin Invest. 1999; 103: 19-25.
• 27 Gross BS, Lee JR, Clements JL, Turner M, Tybulewicz VL, Findell PR, Koretzky GA, Watson SP. Tyrosine phosphorylation of SLP-76 is downstream of syk following stimulation of the collagen receptor in platelets. J Biol Chem. 1999; 274: 5963-5971.
• 28 Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M, Ross FP, Coller BS, Teitelbaum S, Hynes RO. beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999; 103: 229-238.
• 29 Ware J, Russell S, Ruggeri Z. Generation of the Bernard-Soulier syndrome phenotype by genetic disruption of the murine glycoprotein Ib alpha. Blood 1998; 92 (Suppl. 01) 703a.
• 30 Ramakrishnan V, Reeves P, DeGuzman F, Deshpande U, Ministri K, Phillips D. Targeted deletion of the GPV gene in mice: a model for studying the functional role of GPV in mouse platelets. Blood 1998; 92 (Suppl. 01) 349a.
• 31 Ramakrishnan V, Reeves P, DeGuzman F, Minisrti-Madrid K, DuBridge R, Phillips D. GPV is a negative modulator of platelet function. In preparation.
• 32 Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell. 1993; 74: 541-554.
• 33 Subramaniam M, Frenette PS, Saffaripour S, Johnson RC, Hynes RO, Wagner DD. Defects in hemostasis in P-selectin-deficient mice. Blood 1996; 87: 1238-1242.
• 34 Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA. 1995; 92: 7450-7454.
• 35 Massberg S, Enders G, Leiderer R, Eisenmenger S, Vestweber D, Krombach F, Messmer K. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood 1998; 92: 507-515.
• 36 Law D, DeGuzman F, Ministri K, Phillips D. Demonstration of a role for the beta 3 cytoplasmic tyrosine residues in platelet function using mice expressing a mutant (Y747F, Y759F) beta 3. Blood 1998; 92 (Suppl. 01) 701a.
• 37 Law D, DeGuzman F, Ministi-Madrid K, Killeen N, Phillips D. Prevention of beta 3 tyrosine phosphorylation by targeted mutation of the integrin cytoplasmic tyrosine (ICY) motif disrupts normal platelet function through inhibition of outside-in alpha IIb beta 3 signaling. Submitted for publication 1999
• 38 Gabbeta J, Yang X, Kowalska MA, Sun L, Dhanasekaran N, Rao AK. Platelet signal transduction defect with Gα subunit dysfunction and diminished Gαq in a patient with abnormal platelet responses. Proc. Natl. Acad. Sci. USA. 1997; 94: 8750-8755.
• 39 Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in G alpha(q)-deficient mice. Nature 1997; 389: 183-186.
• 40 Aszodi A, Pfeifer A, Ahmad M, Glauner M, Zhou XH, Ny L, Andersson KE, Kehrel B, Offermanns S, Fassler R. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. Embo J. 1999; 18: 37-48.
• 41 Thomas DW, Mannon RB, Mannon PJ, Latour A, Oliver JA, Hoffman M, Smithies O, Koller BH, Coffman TM. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest. 1998; 102: 1994-2001.
• 42 Johnson EN, Brass LF, Funk CD. Increased platelet sensitivity to ADP in mice lacking platelet-type 12- lipoxygenase. Proc Natl Acad Sci USA. 1998; 95: 3100-3105.
• 43 Law DA, Nannizzi-Alaimo L, Ministi K, Hughes PE, Forsyth J, Turner M, Shattil SJ, Ginsberg MH, Tybulewicz VLJ, Phillips DR. Genetic and Pharmacologic Analyses of Syk Function in alphaIIbbeta3 Signaling in Platelets. Blood. 1999; 93: 2645-2659.
• 44 Golden A, Nemeth SP, Brugge JS. Blood platelets express high levels of the pp60c-src-specific tyrosine kinase activity. Proc Natl Acad Sci. USA. 1986; 83: 852-856.
• 45 Horvath AR, Muszbek L, Kellie S. Translocation of pp60c-src to the cytoskeleton during platelet aggregation. Embo J. 1992; 11: 855-861.
• 46 Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991; 64: 693-702.
• 47 Corey SJ, Anderson SM. Src-related protein tyrosine kinases in hematopoiesis. Blood 1999; 93: 1-14.
• 48 Schaller MD, Parsons JT. Focal adhesion kinase and associated proteins. Curr Opin Cell Biol. 1994; 6: 705-710.
• 49 Shattil SJ, Haimovich B, Cunningham M, Lipfert L, Parsons JT, Ginsberg MH, Brugge JS. Tyrosine phosphorylation of pp125FAK in platelets requires coordinated signaling through integrin and agonist receptors. J Biol Chem. 1994; 269: 14738-14745.
• 50 Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995; 377: 539-544.
• 51 Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991; 64: 1057-1068.
• 52 Connolly AJ, Ishihara H, Kahn ML, Farese Jr. RV, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996; 381: 516-519.
• 53 Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386: 502-506.
• 54 Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese Jr. RV, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690-694.
• 55 Jantzen HM, Gousset L, Bhashkar V, Vincent D, Tai A, Reynolds E, Conley P. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. Thromb Haemost. 1999; 81: 111-117.
• 56 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998; 67: 395-424.
• 57 Gralnick H, Connaghan D. Hereditary abnormalities of fibrinogen. McGraw-Hill; New York: 1995: 1439-1454.
• 58 Beacham D, Wise R, Turci S, Handin R. Selective inactivation of the Arg-Gly-Asp-Ser (RGDS) binding site in von Willebrand factor by site-directed mutagenesis. J Biol Chem. 1992; 267: 3409-3415.
• 59 Farrell DH, Thiagarajan P. Binding of recombinant fibrinogen mutants to platelets. J Biol Chem. 1994; 269: 226-231.
• 60 Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI, Potter S, Degen JL. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 1995; 9: 2020-2033.
• 61 Holmback K, Danton MJ, Suh TT, Daugherty CC, Degen JL. Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3. Embo J. 1996; 15: 5760-5771.
• 62 Rooney MM, Parise LV, Lord ST. Dissecting clot retraction and platelet aggregation. Clot retraction does not require an intact fibrinogen g chain C terminus. J Biol Chem. 1996; 271: 8553-8555.
• 63 Rooney MM, Farrell DH, van Hemel BM, de Groot PG, Lord ST. The contribution of the three hypothesized integrin-binding sites in fibrinogen to platelet-mediated clot retraction. Blood 1998; 92: 2374-2381.
• 64 Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Cullere M, Hynes RO, Wagner DD. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA. 1998; 95: 9524-9529.
• 65 Mohri H, Ohkubo T. How vitronectin binds to activated glyco-protein IIb-IIIa complex and its function in platelet aggregation. Am J Clin Pathol. 1991; 96: 605-609.
• 66 Asch E, Podack E. Vitronectin binds to activated human platelets and plays a role in platelet aggregation. J Clin Invest. 1990; 85: 1372-1378.
• 67 Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 1999; 93: 1825-1830.
• 68 Kieffer N, Nurden AT, Hasitz M, Titeux M, Breton-Gorius J. Identification of platelet membrane thrombospondin binding molecules using an anti-thrombospondin antibody. Biochim Biophys Acta. 1988; 967: 408-415.
• 69 Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem. 1996; 271: 21-24.
• 70 Dixit VM, Haverstick DM, O’Rourke KM, Hennessy SW, Grant GA, Santoro SA, Frazier WA. A monoclonal antibody against human thrombospondin inhibits platelet aggregation. Proc Natl Acad Sci USA. 1985; 82: 3472-3476.
• 71 Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, Hynes RO. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest. 1998; 101: 982-992.
• 72 Kyriakides TR, Zhu YH, Smith LT, Bain SD, Yang Z, Lin MT, Danielson KG, Iozzo RV, LaMarca M, McKinney CE, Ginns EI, Bornstein P. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol. 1998; 140: 419-430.
• 73 Bonthu S, Heistad DD, Chappell DA, Lamping KG, Faraci FM. Atherosclerosis, vascular remodeling, and impairment of endothelium- dependent relaxation in genetically altered hyper-lipidemic mice. Arterioscler Thromb Vasc Biol. 1997; 17: 2333-2340.
• 74 Kumar A, Hoover JL, Simmons CA, Lindner V, Shebuski RJ. Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice [see comments]. Circulation. 1997; 96: 4333-4342.
• 75 Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell. 1998; 95: 507-519.
• 76 Fassler R, Pfaff M, Murphy J, Noegel AA, Johansson S, Timpl R, Albrecht R. Lack of beta 1 integrin gene in embryonic stem cells affects morphology, adhesion, and migration but not integration into the inner cell mass of blastocysts. J Cell Biol. 1995; 128: 979-988.
• 77 Lindberg FP, Bullard DC, Caver TE, Gresham HD, Beaudet AL, Brown EJ. Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice. Science 1996; 274: 795-798.
• 78 Tarakhovsky A, Turner M, Schaal S, Mee PJ, Duddy LP, Rajewsky K, Tybulewicz VL. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. Nature 1995; 374: 467-470.
• 79 Appleby MW, Kerner JD, Chien S, Maliszewski CR, Bondada S, Perlmutter RM, Bondadaa S. Involvement of p59fynT in interleukin-5 receptor signaling. J Exp Med. 1995; 182: 811-820.
• 80 Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, Stacker SA, Dunn AR. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell. 1995; 83: 301-311.
• 81 George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development. 1993; 119: 1079-1091.
• 82 Law DA, Nannizzi-Alaimo L, Phillips DR. Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation. J Biol Chem. 1996; 271: 10811-10815.
• 83 Jenkins A, Nannizzi-Alaimo L, Silver D, Sellers J, Ginsberg M, Law D, Phillips D. Tyrosine phosphorylation of the β3 cytoplasmic domain mediates integrin-cytoskeletal interactions. J Biol Chem. 1998; 273: 13878-13885.